NOVEL PARADIGMS FOR DRUG DISCOVERY: COMPUTATIONAL MULTITARGET SCREENING

药物发现的新范式:计算多目标筛选

基本信息

  • 批准号:
    8146021
  • 负责人:
  • 金额:
    $ 82.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-30 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION Abstract: We will create a comprehensive computational drug discovery platform by enhancing a novel technique for a dynamic, fragment based, screening of small molecule compounds against the three dimensional structures of multiple protein targets from infectious disease causing pathogens, followed by prospective in vitro and in vivo experimental verification. We will further modify the most promising lead candidates computationally and screen them against all known human proteins and variants simultaneously to assess for side effects against essential proteins, and to ensure that they possess safe and effective absorption, distribution, metabolism, and excretion profiles against major proteins in known drug delivery pathways. The top ranking leads will again be experimentally verified, and the computational protocol will be itera- tively refined using machine learning techniques. We will initially focus on discovering preclinical drug candidates against infections caused by all eight human herpes viruses (HHVs). This virus family infects billions of humans worldwide every year and is the source of significant mortality in immunocompromised patients. Broad spectrum therapeutics against these key pathogens will benefit the entire global community. In contrast to other computational efforts, my group has successfuly applied and experimentally verified their predictions of inhibitors to treat herpes, malaria, and dengue. This was accomplished at a fraction of the time, effort, and cost typically required by pharmaceutical companies. Our significant successes thus far attest to the efficacy of our drug discovery technologies. The Pioneer Award funds will therefore allow us to bridge the gap of discovering computationally predicted lead compounds and demonstrating their preclinical effectiveness for further clinical and therapeutic use. The ultimate goal is to create a comprehensive computational drug discovery pipeline, applicable to any disease, thereby increasing the suc
描述 摘要: 我们将创建一个全面的计算药物发现平台,通过增强一种新的技术,用于动态的,基于片段的,针对引起感染性疾病的病原体的多个蛋白质靶点的三维结构筛选小分子化合物,然后进行前瞻性的体外和体内实验验证。我们将通过计算进一步修改最有希望的先导候选物,并同时对所有已知的人类蛋白质和变体进行筛选,以评估对必需蛋白质的副作用,并确保它们对已知药物递送途径中的主要蛋白质具有安全有效的吸收,分布,代谢和排泄特征。排名靠前的线索将再次通过实验验证,计算方案将使用机器学习技术进行迭代优化。我们最初将专注于发现针对所有八种人类疱疹病毒(HHV)引起的感染的临床前候选药物。该病毒家族每年感染全球数十亿人,是免疫功能低下患者的重大死亡原因。针对这些关键病原体的广谱疗法将使整个全球社会受益。与其他计算工作相反,我的团队成功地应用并实验验证了他们对治疗疱疹、疟疾和登革热的抑制剂的预测。这是在一小部分的时间,精力和成本通常所需的制药公司。我们迄今取得的重大成功证明了我们药物发现技术的有效性。因此,先锋奖基金将使我们能够弥合发现计算预测的先导化合物和证明其临床前有效性以进一步临床和治疗用途的差距。最终目标是创建一个全面的计算药物发现管道,适用于任何疾病,从而增加药物的有效性。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Promise and Challenge of Digital Biology.
数字生物学的前景和挑战。
Multiscale modelling of relationships between protein classes and drug behavior across all diseases using the CANDO platform.
  • DOI:
    10.2174/1389557515666150219145148
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sethi G;Chopra G;Samudrala R
  • 通讯作者:
    Samudrala R
LoCo: a novel main chain scoring function for protein structure prediction based on local coordinates.
LoCo:一种基于局部坐标的蛋白质结构预测的新型主链评分函数。
  • DOI:
    10.1186/1471-2105-12-368
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Moughon,StewartE;Samudrala,Ram
  • 通讯作者:
    Samudrala,Ram
Rv0100, a proposed acyl carrier protein in Mycobacterium tuberculosis: expression, purification and crystallization. Corrigendum.
Rv0100,结核分枝杆菌中拟议的酰基载体蛋白:表达、纯化和结晶。
  • DOI:
    10.1107/s2053230x2000271x
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bondoc,JasperMarcG;Gutka,HitenJ;Almutairi,MashalM;Patwell,Ryan;Rutter,MaxwellW;Wolf,NinaM;Samudrala,Ram;Mehboob,Shahila;Dementiev,Alexey;Abad-Zapatero,Cele;Movahedzadeh,Farahnaz
  • 通讯作者:
    Movahedzadeh,Farahnaz
Linking Genome and Exposome: Computational Analysis of Human Variation in Chemical-Target Interactions.
连接基因组和暴露组:化学靶标相互作用中人类变异的计算分析。
  • DOI:
    10.3233/shti200427
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bruggemann,Liana;Hawthorne,Christopher;Samudrala,Ram;Lopez-Campos,GuillermoH
  • 通讯作者:
    Lopez-Campos,GuillermoH
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAM SAMUDRALA其他文献

RAM SAMUDRALA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAM SAMUDRALA', 18)}}的其他基金

Novel Paradigms For Drug Discovery: Computational Multitarget Screening
药物发现的新范式:计算多靶点筛选
  • 批准号:
    9015936
  • 财政年份:
    2010
  • 资助金额:
    $ 82.17万
  • 项目类别:
NOVEL PARADIGMS FOR DRUG DISCOVERY: COMPUTATIONAL MULTITARGET SCREENING
药物发现的新范式:计算多目标筛选
  • 批准号:
    8703178
  • 财政年份:
    2010
  • 资助金额:
    $ 82.17万
  • 项目类别:
NOVEL PARADIGMS FOR DRUG DISCOVERY: COMPUTATIONAL MULTITARGET SCREENING
药物发现的新范式:计算多目标筛选
  • 批准号:
    8306129
  • 财政年份:
    2010
  • 资助金额:
    $ 82.17万
  • 项目类别:
NOVEL PARADIGMS FOR DRUG DISCOVERY: COMPUTATIONAL MULTITARGET SCREENING
药物发现的新范式:计算多目标筛选
  • 批准号:
    8509784
  • 财政年份:
    2010
  • 资助金额:
    $ 82.17万
  • 项目类别:
NOVEL PARADIGMS FOR DRUG DISCOVERY: COMPUTATIONAL MULTITARGET SCREENING
药物发现的新范式:计算多目标筛选
  • 批准号:
    7979181
  • 财政年份:
    2010
  • 资助金额:
    $ 82.17万
  • 项目类别:
Protein structure from theory and experiment
理论和实验的蛋白质结构
  • 批准号:
    6635369
  • 财政年份:
    2003
  • 资助金额:
    $ 82.17万
  • 项目类别:
Protein structure from theory and experiment
理论和实验的蛋白质结构
  • 批准号:
    6888939
  • 财政年份:
    2003
  • 资助金额:
    $ 82.17万
  • 项目类别:
Protein structure from theory and experiment
理论和实验的蛋白质结构
  • 批准号:
    6738961
  • 财政年份:
    2003
  • 资助金额:
    $ 82.17万
  • 项目类别:

相似海外基金

Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 82.17万
  • 项目类别:
Einstein-Montefiore Clinical and Translational Science Award Hub
爱因斯坦-蒙蒂菲奥里临床和转化科学奖中心
  • 批准号:
    10622099
  • 财政年份:
    2023
  • 资助金额:
    $ 82.17万
  • 项目类别:
University of Kansas Cancer Center Paul Calabresi K12 Career Development Award for Clinical Oncology
堪萨斯大学癌症中心 Paul Calabresi K12 临床肿瘤学职业发展奖
  • 批准号:
    10647369
  • 财政年份:
    2023
  • 资助金额:
    $ 82.17万
  • 项目类别:
Institutional Clinical and Translational Sciences Award
机构临床和转化科学奖
  • 批准号:
    10487653
  • 财政年份:
    2022
  • 资助金额:
    $ 82.17万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10674531
  • 财政年份:
    2022
  • 资助金额:
    $ 82.17万
  • 项目类别:
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖
  • 批准号:
    10434380
  • 财政年份:
    2022
  • 资助金额:
    $ 82.17万
  • 项目类别:
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖
  • 批准号:
    10623252
  • 财政年份:
    2022
  • 资助金额:
    $ 82.17万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10656986
  • 财政年份:
    2022
  • 资助金额:
    $ 82.17万
  • 项目类别:
Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS
研究计划奖(R35 临床试验可选)- Robyn Klein NINDS 博士
  • 批准号:
    10397683
  • 财政年份:
    2021
  • 资助金额:
    $ 82.17万
  • 项目类别:
Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS
研究计划奖(R35 临床试验可选)- Robyn Klein NINDS 博士
  • 批准号:
    10239672
  • 财政年份:
    2021
  • 资助金额:
    $ 82.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了